PRTA - Prothena Corporation plc
NASDAQ
->
Healthcare
->
Biotechnology
Dublin,
Ireland
Type: Equity
PRTA price evolution
PRTA
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $564.12 | $547.86 | $620.18 | |
| Short term investments | ||||
| Net receivables | $5.16 | |||
| Inventory | ||||
| Total current assets | $534.98 | $585.98 | $565.87 | $639.28 |
| Long term investments | $0.86 | $0.86 | $0.86 | |
| Property, plant & equipment | $14.65 | $15.55 | $16.18 | $16 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $59.59 | $57.33 | $57.1 | |
| Total investments | $0.86 | $0.86 | $0.86 | |
| Total assets | $595.25 | $645.57 | $623.19 | $696.38 |
| Current liabilities | ||||
| Accounts payable | $10.33 | $9.29 | $14.42 | $25.39 |
| Deferred revenue | $15.39 | $67.41 | $67.41 | |
| Short long term debt | $2.58 | $2.37 | $1.11 | |
| Total current liabilities | $46.42 | $46.74 | $43.27 | $56.89 |
| Long term debt | $9.54 | $10.12 | $10.72 | |
| Total noncurrent liabilities | $16.9 | $77.53 | $78.13 | |
| Total debt | $12.12 | $12.5 | $11.84 | |
| Total liabilities | $60.89 | $63.65 | $120.8 | $135.02 |
| Shareholders' equity | ||||
| Retained earnings | -$1044.38 | -$985.38 | -$1052.27 | -$980.03 |
| Other shareholder equity | $561.37 | |||
| Total shareholder equity | $581.92 | $502.4 | $561.37 | |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $620.18 | $710.41 | $579.09 | $296.73 |
| Short term investments | ||||
| Net receivables | $5.16 | $0.01 | ||
| Inventory | ||||
| Total current assets | $639.28 | $719.1 | $584.81 | $299.28 |
| Long term investments | $0.86 | $2.21 | $1.35 | $1.35 |
| Property, plant & equipment | $16 | $8.01 | $14.13 | $20.36 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $57.1 | $38.94 | $24.56 | $33.69 |
| Total investments | $0.86 | $2.21 | $1.35 | $1.35 |
| Total assets | $696.38 | $758.03 | $609.37 | $332.98 |
| Current liabilities | ||||
| Accounts payable | $25.39 | $9.27 | $3.69 | $4.12 |
| Deferred revenue | $67.41 | $96.73 | $110.59 | $110.24 |
| Short long term debt | $1.11 | $6.47 | $5.94 | $5.51 |
| Total current liabilities | $56.89 | $50.15 | $33.45 | $25.85 |
| Long term debt | $10.72 | $6.39 | $12.33 | |
| Total noncurrent liabilities | $78.13 | $85.85 | $109.87 | $123.12 |
| Total debt | $11.84 | $6.47 | $12.33 | $17.84 |
| Total liabilities | $135.02 | $135.99 | $143.32 | $148.97 |
| Shareholders' equity | ||||
| Retained earnings | -$980.03 | -$833 | -$716.05 | -$783.03 |
| Other shareholder equity | $561.37 | $466.04 | ||
| Total shareholder equity | $561.37 | $622.04 | $466.04 | $184.01 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $132.01 | $0.05 | $0.32 | |
| Cost of revenue | ||||
| Gross Profit | $132.01 | $0.05 | ||
| Operating activities | ||||
| Research & development | $57.51 | $64.11 | ||
| Selling, general & administrative | $16.13 | $17.46 | ||
| Total operating expenses | $73.64 | $81.58 | $78.83 | |
| Operating income | $58.38 | -$81.53 | ||
| Income from continuing operations | ||||
| EBIT | $64.85 | -$74.44 | ||
| Income tax expense | -$2.04 | -$2.2 | -$3.14 | |
| Interest expense | ||||
| Net income | ||||
| Net income | $66.89 | -$72.24 | -$67.48 | |
| Income (for common shares) | $66.89 | -$72.24 | ||
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $91.37 | $53.91 | $0.85 | |
| Cost of revenue | ||||
| Gross Profit | $53.91 | $0.85 | ||
| Operating activities | ||||
| Research & development | $135.56 | $74.88 | ||
| Selling, general & administrative | $49.9 | $38.7 | ||
| Total operating expenses | $282.41 | $185.46 | $113.59 | |
| Operating income | -$131.56 | -$112.73 | ||
| Income from continuing operations | ||||
| EBIT | -$125.61 | -$111.43 | ||
| Income tax expense | -$13.45 | -$8.66 | -$0.28 | |
| Interest expense | ||||
| Net income | ||||
| Net income | -$147.03 | -$116.95 | -$111.14 | |
| Income (for common shares) | -$116.95 | -$111.14 | ||
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $66.89 | -$72.24 | -$67.48 | |
| Operating activities | ||||
| Depreciation | $0.89 | $0.89 | $2.54 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $12.04 | $12.38 | $11.08 | |
| Total cash flows from operations | $15.96 | -$73.05 | -$51.04 | |
| Investing activities | ||||
| Capital expenditures | -$0.14 | -$0.1 | -$1.51 | |
| Investments | ||||
| Total cash flows from investing | -$0.26 | -$0.14 | -$0.1 | -$1.51 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.44 | $0.84 | $0.48 | |
| Net borrowings | ||||
| Total cash flows from financing | $1.61 | $0.44 | $0.84 | $0.48 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$100.92 | $16.26 | -$72.32 | -$52.07 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$147.03 | -$116.95 | $66.97 | -$111.14 |
| Operating activities | ||||
| Depreciation | $8.41 | $6.74 | $6.8 | $6.98 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $40.91 | $31.32 | $24.66 | $22.01 |
| Total cash flows from operations | -$133.91 | -$108.82 | $92.61 | -$80.36 |
| Investing activities | ||||
| Capital expenditures | -$2.77 | -$0.46 | -$0.57 | -$0.2 |
| Investments | ||||
| Total cash flows from investing | -$2.77 | -$0.46 | -$0.57 | -$0.2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $45.1 | $241.46 | $190.33 | $0.21 |
| Net borrowings | ||||
| Total cash flows from financing | $45.1 | $241.46 | $190.33 | $0.21 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$91.58 | $132.17 | $282.36 | -$80.34 |
News
Fundamentals
| Market cap | $494.50M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 53.81M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.24 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 11.52 |
| Quick ratio | N/A |